SNAP-based Program

About Barinthus Biotherapeutics

Barinthus Biotherapeutics is a UK-based clinical-stage biotech formed in 2021 from the merger of Vaccitech plc and Avidea Technologies, combining complementary immunotherapeutic technologies. The company's mission is to advance antigen-specific immunotherapies that guide T cells to overcome autoimmunity and inflammatory diseases. It has reported positive interim and final data from Phase 1b/2 studies in hepatitis B and HPV, demonstrating favorable tolerability and immunogenicity. Barinthus is publicly traded (NASDAQ: BRNS) and is building a pipeline focused on immunology and inflammatory (I&I) indications.

Therapeutic Areas

Other Celiac Disease Drugs